Bibliografía del artículo
1. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R y col. Increasing mortality due to end-stage liver disease in patients with human immunodeficiency virus infection. Clin Infect Dis 32:492-497, 2001.
2. Camino X, Iribarren JA, Arrizabalaga J, Rodríguez F, von Wichmann AM. Causes of mortality among patients infected with the human immunodeficiency virus in the era of high active antiretroviral therapy. Enferm Infecc Microbiol Clin 19:85-86, 2001.
3. Soriano V, García Samaniego J, Bravo R, Valencia E, Laguna F, Pouplana M y col. Morbilidad y mortalidad asociadas a hepatopatía crónica viral en pacientes infectados por el virus de la inmunodeficiencia humana. Med Clin (Bar) 104:641-644, 1995.
4. Pineda JA, Romero-Gómez M, Díaz-García, Girón-González JA, Montero JL, Torre-Cisneros J y col. HIV coinfection shortens the survival of patients with hepatitis C virus-related decompesated cirrosis. Hepatology 41:779-789, 2005.
5. Pérez-Olmeda M, Núñez M, Romero M, González J, Castro A, Arribas JR y col. Pegylated IFN-a2b plus ribavirin as therapy for chronic hepatitis C in HIV-infected patients. AIDS 17:1023-1028, 2003.
6. Moreno L, Quereda C, Moreno A, Pérez-Elías MJ, Antela A, Casado JL y col. Pegylated interferon a2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. AIDS 18:67-73, 2004.
7. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A y col. Pegylated-interferon-alfa-2b versus standard interferon-alfa-2b plus ribavirin for chronic hepatitis c in hiv infected patients: a randomized controlled trial. JAMA 292:2839-2948, 2004.
8. Torriani FJ, Rodríguez-Torres M, Rockstroh JK, Lisse E, González-García J, Lazzarin A y col. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N Engl J Med 351:438-450, 2004.
9. Berenguer J, González-García J, López-Aldeguer J, von-Wichmann MA, Quereda C, Hernando A y col. Pegylated interferon {alpha}2a plus ribavirin versus pegylated interferon {alpha}2b plus ribavirin for the treatment of chronic hepatitis C in HIV-infected patients. J Antimicrob Chemother 63:1256-1263, 2009.
10. Berenguer J, Rodríguez E, Miralles P, von-Wichmann MA, López-Aldeguer J, Mallolas P y col. Sustained virological response to interferon plus ribavirin reduces non-liver-related mortality in patients co-infected with HIV and HCV. Clin Infect Dis 55:728-736, 2012.
11. Ziol M, Handra-Luca A, Kettaneh A, Christidis C, Mal F, Kazemi F y col. Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with chronic hepatitis C. Hepatology 41:48-54, 2005.
12. Pineda JA, González J, Ortega E, Tural C, Macías J, Griffa L y col. Prevalence and factors associated with significant liver fibrosis assessed by transient elastometry in HIV/hepatitis C virus-coinfected patients. J Viral Hepat 17:714-719, 2010.
13. Sánchez-Conde M, Montes-Ramírez ML, Miralles P, Alvarez JM, Bellón JM, Ramírez M y col. Comparison of transient elastography and liver biopsy for the assessment of liver fibrosis in HIV/hepatitis C virus-coinfected patients and correlation with noninvasive serum markers. Journal of Viral Hepatitis 17:280-286, 2010.
14. Iloeje UH, Yang HI, Su J, Jen CL, You SL, Chen CJ. Predicting cirrosis risk based on the level of circulating hepatitis B viral load. Gastroenterology 130:678-686, 2006.
15. Tural C, Fuster D, Tor J, Ojanguren J, Sirera G, Ballesteros A y col. Time on antiretroviral therapy is a protective factor for liver fibrosis in HIV and hepatitis C virus (HCV) co-infected patients. J Viral Hepat 10:118-125, 2003.
16. Benhamou Y, Di Martino V, Bochet M, Colombet G, Thibault V, Liou A y col. Factors affecting liver fibrosis in human immunodeficiency virus- and hepatitis C virus-coinfecetd patients: impact of protease inhibitor therapy. Hepatology 34:283-287, 2001.
17. Martín-Carbonero I, Benhamou Y, Puoti M, Berenguer J, Mallolas J, Quereda C y col. Incidence and predictors of severe liver fibrosis in human immunodefienciy virus-infected patients with chronic hepatitis C: a European collaborative study. Clin Infect Dis 38:128-133, 2004.
18. Ibáñez JG, Pérez M, Lamas JL, Ocampo A, Vázquez CM, Ribera A. Estudio de concordancia en el grado de fibrosis hepática estimada mediante los índices bioquímicos APRI y FORNS y la elastografía de transición (Fibroscan) en pacientes coinfectados por VIH-VHC. Rev Clin Esp 210:317-322, 2010.
19. González-Guilabert ML, Hinojosa Mena-Bernal C, del Pozo González J, del Pozo Pérez MA. Estudio retrospectivo de la capacidad de evaluación de fibrosis hepática del FibroScan, APRI, FIB-4 y FORNS con referencia a la biopsia hepática de pacientes con hepatitis crónica C, mono y coinfectados con VIH. Gastroenterol Hepatol 33:425-432, 2010.
20. Vergara S, Macias J, Rivero A, Gutiérrez-Valencia A, González-Serrano M, Merino D y col. The use of transient elastometry for assessing liver fibrosis in patients with HIV and hepatitis C virus coinfection. Clin Infect Dis 45:969-974, 2007.
21. Pérez-Olmeda M, Ríos P, Núñez M, García-Samaniego J, Romero M, Soriano V. Virological characteristics of hepatitis C virus infection in HIV-infected individuals with chronic hepatitis C: implications for treatment. AIDS 16:493-495, 2002.
22. Puoti M, Bonacini M, Spinetti A, Putzolo V, Govindarajan S, Zaltron S y col. Liver fibrosis progression is related to CD4 cell depletion in patients coinfected with hepatitis C virus and human immunodeficiency virus. J Infect Dis 183:134-137, 2001.
23. Merchante N, Girón-González JA, González-Serrano M, Torre-Cisneros J, García-García JA, Arizcorreta A y col. Survival and prognostic factors of HIV-infected patients with HCV-related end-stage liver disease. AIDS 20;49-57, 2006.
24. Massard J, Ratziu V, Thabut D, Moussalli J, Lebray P, Benhamou Y et al. Natural history and predictors of disease severity in chronic hepatitis C. J Hepatolog 44(1 Suppl):S19-24, 2006.
25. Mariné-Barjoan E, Saint-Paul MC, Pradier C, Chaillou S, Anty R, Michiels JF y col. Impact of antiretroviral treatment on progression of hepatitis fibrosis in HIV/hepatitis C virus co-infected patients. AIDS 18:2163-2170, 2004.
26. Carrión JA, Navas M, Buti M, Torras X, Xiol X, Vergara M y col. Elastografía hepática. Documento de posicionamiento de la Societat Catalana de Digestologia. Gastroenterol Hepatol 34:504-510, 2011.